Guideline for Evaluation of a Solitary Liver Lesion Dominated by Histiocytes

Infectious Lesions

Hepatic abscesses (pyogenic or amebic) commonly show histiocytic infiltration with necrosis; fever and elevated inflammatory markers should raise suspicion. [1][2][3][4]
On imaging, pyogenic abscesses may contain intralesional gas due to gas‑forming bacteria, whereas amebic cysts typically appear as hypodense, water‑density lesions. [1][2]3

Langerhans cell histiocytosis (LCH) of the liver frequently harbors MAPK pathway mutations, most notably BRAF‑V600E in 36–50 % of cases; molecular testing is recommended when LCH is suspected. 5
Rosai‑Dorfman disease (RDD) may present with hepatic involvement and often requires multidisciplinary evaluation and additional biopsies of atypical sites to confirm diagnosis. [5][6]

Hepatocellular carcinoma (HCC) arising in a non‑cirrhotic liver demands histopathologic confirmation because imaging specificity is reduced compared with cirrhotic livers; stromal invasion on biopsy defines malignancy. [7][4]
Cholangiocarcinoma can appear as a solid liver lesion with minimal vascular enhancement; immunohistochemical staining for cytokeratin 19 assists in identifying biliary differentiation. [1][3]4
Metastatic liver disease may mimic benign lesions: hypervascular metastases (e.g., from thyroid or neuroendocrine tumors) and typically hypoattenuating lesions on CT require systematic immunohistochemical work‑up to determine the primary site. [1][2]

Assess clinical context—including presence or absence of cirrhosis, risk factors for chronic liver disease, fever, and constitutional symptoms—to narrow the differential. [1][2]
Order baseline laboratory tests such as alpha‑fetoprotein (AFP), liver function panel, and inflammatory markers to aid lesion characterization. 4
Evaluate imaging features (dynamic CT/MRI) for vascular pattern, central scar, and calcification; these characteristics help differentiate benign from malignant processes. [1][2]8

Examine biopsy architecture for stromal invasion and portal tract involvement; these findings are critical for diagnosing malignancy. 4
Apply special stains—CD34 for neovascularization and glypican‑3 for HCC differentiation—to improve diagnostic accuracy. 4
Utilize immunohistochemistry: cytokeratin 19 for biliary features, and disease‑specific markers for histiocytic neoplasms (e.g., CD1a, S100). [4][5]
Perform molecular testing for MAPK pathway mutations (e.g., BRAF‑V600E) when a histiocytic neoplasm is in the differential. [5][6]

Do not rely solely on imaging or necrotic biopsy material to label a lesion malignant; solitary necrotic nodules can mimic metastases.
In patients without cirrhosis, the lower specificity of typical HCC imaging mandates histologic confirmation. 7
Consider mixed histiocytoses (e.g., overlap of LCH with RDD or Erdheim‑Chester disease); additional biopsies of atypical sites may be necessary. 5

Alpha‑fetoprotein (AFP) > 200 ng/mL strongly suggests hepatocellular carcinoma (HCC); however, approximately 46 % of HCC patients may have normal AFP levels. – evidence from a cohort of patients with focal liver lesions 9

Obtain a multiphasic contrast‑enhanced CT or MRI immediately to characterize the hepatic lesion and to evaluate for metastatic disease. – first‑line imaging protocol for adults with a focal liver lesion 10
In HCC, the classic vascular hallmark is arterial‑phase hyperenhancement followed by portal‑ or delayed‑phase washout. – diagnostic imaging feature in non‑cirrhotic livers [9][11]
In non‑cirrhotic livers, the specificity of imaging for HCC is significantly reduced; therefore, histologic confirmation is mandatory. – recommendation for tissue diagnosis when imaging is equivocal 9
Single‑phase CT or ultrasound alone is insufficient; multiphasic imaging is required for accurate lesion characterization. – imaging standard endorsed by hepatology and radiology societies [11][12]

Biopsy is indicated when imaging findings are atypical or inconclusive, when the patient has no underlying cirrhosis, or when clinical features (e.g., fever) conflict with imaging suggestive of HCC. – criteria for tissue sampling [9][10]
Percutaneous biopsy of potentially resectable lesions carries a 1–3 % risk of needle‑tract tumor seeding. – safety consideration for biopsy planning [13][10]
In patients with decompensated cirrhosis who are transplant candidates, biopsy adds no diagnostic value and is therefore not recommended. – contraindication in advanced liver disease 9
When biopsy is performed, expert pathology should assess stromal invasion, CD34 staining for neovascularization, and glypican‑3 expression to confirm HCC. – histopathologic criteria for definitive diagnosis 9